Personalized Dendritic Cell Vaccine Launches Melanoma Trial After Anti-PD-1 Treatment Failure

Immune checkpoint inhibitors have transformed the treatment of advanced melanoma, but not all patients experience lasting benefit. When tumors progress again after anti-PD-1 treatment, the available options rapidly diminish. HonorHealth Research Institute has now joined a multicenter trial evaluating whether a vaccine tailored to the characteristics of each individual’s cancer can be made using the patient’s own immune cells and tumor material.

The investigational therapy is called DOC1021, also known as dubodencel. The trial is sponsored by Diakonos Oncology, has the registration number NCT07288112, and is currently enrolling participants in Phase 1/2. The initial cohorts will first assess the safety and tolerability of DOC1021 in combination with pegylated interferon, followed by a single-arm Phase 2 cohort evaluating tumor response.

The manufacturing process for DOC1021 begins with the patient. The research team collects cells from the patient’s blood and cultures them into dendritic cells, which are responsible for presenting antigens. The cells are then loaded with both tumor lysate and amplified mRNA obtained from the tumor. These materials encompass multiple antigens within the patient’s tumor. Rather than targeting a single mutation, the vaccine is designed to enable dendritic cells to present a broader range of cancer-cell characteristics to T cells, thereby inducing an antitumor immune response.

According to publicly available trial information from the US National Cancer Institute, after undergoing leukapheresis, participants will receive two image-guided DOC1021 injections two weeks apart, alongside four weekly subcutaneous injections of pegylated interferon. Approximately six months later, participants may elect to receive one additional DOC1021 booster and two interferon injections. Imaging, blood markers, symptoms, and quality of life will also be monitored during the study.

The trial primarily includes patients aged 18 or older with unresectable or metastatic melanoma whose disease has worsened after at least one systemic treatment regimen containing an anti-PD-1 drug. Because the vaccine must be made using each patient’s own tumor material, patients must also have a lesion available for biopsy or resection and another target lesion that can be measured to assess treatment efficacy. Patients with brain metastases that remain stable after treatment may also be eligible.

At present, the study can only establish the treatment concept and trial progress; no safety or efficacy results are yet available from patients with melanoma. The subsequent Phase 2 portion also uses a single-arm design, meaning that even if signals of tumor shrinkage emerge, the respective effects of the vaccine, interferon, and other treatments will still need to be distinguished cautiously. The tumor specimens, leukocyte collection, and processing time required for personalized manufacturing may likewise limit accessibility. Whether DOC1021 can truly expand the options available to patients for whom anti-PD-1 treatment has failed cannot be determined until actual enrollment and clinical data are available.